Candel Therapeutics, Inc. remains a Buy as its lead asset, CAN-2409, advances toward FDA submission

NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

NEEDHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

Stifel analyst Stephen Willey initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Buy

NEEDHAM, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

Candel Therapeutics is transitioning from a high-risk clinical-stage biotech to a late-stage oncolog

NEEDHAM, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical

Phase 3 clinical trial will evaluate aglatimagene besadenovec plus valacyclovir in combination with

NEEDHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

Peer reviewed publication details pivotal data, demonstrating 30% improvement in disease-free surviv

NEEDHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

NEEDHAM, Mass. , June 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

Candel Therapeutics NASDAQ: CADL Chief Executive Officer Dr. Paul Peter Tak said the company remains

The mean of analysts' price targets for Candel Therapeutics (CADL) points to a 148.5% upside in the

Candel Therapeutics presented positive phase 3 prostate cancer data showing improved disease-free su

Candel Therapeutics, Inc. (CADL) Discusses Extended Follow-Up Data From Phase 3 Trial of aglatimagen

Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow

NEEDHAM, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (

Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.14) per share which beat the anal

NEEDHAM, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (

NEEDHAM, Mass. , May 13, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)

Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical

Candel Therapeutics ripped higher on Monday after a bullish analyst initiation, underscoring how nar

Citigroup analyst Yigal Nochomovitz maintains Candel Therapeutics (NASDAQ:CADL) with a Buy and ra

Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clini

Citigroup analyst Yigal Nochomovitz maintains Candel Therapeutics (NASDAQ:CADL) with a Buy and lo

Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.54) per share which missed the an

Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical

(Editor's note: The future prices of benchmark tracking ETFs, the lede, and the headline were up

Candel Therapeutics stock down on public offering pricing, intends to use proceeds for cancer therap

GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards

Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-th

  Wednesday saw 59 companies set new 52-week lows.

  During Thursday's trading, 110 companies set new 52-week lows.

  During Wednesday's trading, 517 companies set new 52-week lows.

  On Thursday, 588 stocks hit new 52-week lows.

    On Friday, 209 companies set new 52-week lows.